RxDoctor Payments Data

Michael Maier, DPM

Podiatrist · Cleveland, OHNPI 1548323686

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $74,526 of the $119,705 with a category attached, or 62.3%. Smith+Nephew accounts for 85.5% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $46,264 and has fallen 72.9% since, to $12,516 in 2024. Among podiatrist clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$119,705in general payments, 2019–2025

Across 188 payments — averaging $636.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$102K
  • Wound Management Technologies, Inc$7K
  • Modulated Imaging, Inc.$5K
  • KCI USA, Inc.$3K
  • Sanara Medtech Inc.$2K
  • Organogenesis Inc.$21

What the payments were for

  • Consulting fees$19,21816%
  • Speaking & faculty fees$74,52662%
  • Travel & lodging$22,59519%
  • Food & beverage$3,3673%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Smith+Nephew172$102,364
Wound Management Technologies, Inc4$6,832
Modulated Imaging, Inc.8$5,204
KCI USA, Inc.2$3,285
Sanara Medtech Inc.1$2,000
Organogenesis Inc.1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$119,705 in reported general payments places this provider in the 95th percentile of 397 podiatrist providers in Ohio.

See all podiatrist providers in Ohio

Medicare billing

Part B allowed, 2024
$23,155
Medicare patients
194
Services billed
524

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.24$13,903
Fluocinonide15$812
Triamcinolone Acetonide55$353
Doxycycline Monohydrate16$196
Gabapentin12$104

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$102,364$13,90324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 397 podiatrist providers in Ohio.

Other podiatrist in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →